Miguel Regueiro, MD
Switching to and between biosimilar versions of infliximab does not affect the effectiveness or safety of treatment in patients with inflammatory bowel disease, according to two studies presented at the 2021 virtual Digestive Disease Week.
“Based on these and previous studies, no one—whether patient, provider or insurer—should worry about a one-time switch to a biosimilar of infliximab, and preliminary evidence suggests multiple switches seem to be fine, at